CA2563192A1 - Tri(cyclo) substituted amide compounds - Google Patents

Tri(cyclo) substituted amide compounds Download PDF

Info

Publication number
CA2563192A1
CA2563192A1 CA002563192A CA2563192A CA2563192A1 CA 2563192 A1 CA2563192 A1 CA 2563192A1 CA 002563192 A CA002563192 A CA 002563192A CA 2563192 A CA2563192 A CA 2563192A CA 2563192 A1 CA2563192 A1 CA 2563192A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
2alkyl
group
acceptable salt
fluorothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002563192A
Other languages
English (en)
French (fr)
Inventor
Matthew Fyfe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prosidion Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2563192A1 publication Critical patent/CA2563192A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002563192A 2004-04-21 2005-04-19 Tri(cyclo) substituted amide compounds Abandoned CA2563192A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56417104P 2004-04-21 2004-04-21
US60/564,171 2004-04-21
US60107704P 2004-08-12 2004-08-12
US60/601,077 2004-08-12
PCT/GB2005/050053 WO2005103021A1 (en) 2004-04-21 2005-04-19 Tri(cyclo) substituted amide compounds

Publications (1)

Publication Number Publication Date
CA2563192A1 true CA2563192A1 (en) 2005-11-03

Family

ID=34965439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002563192A Abandoned CA2563192A1 (en) 2004-04-21 2005-04-19 Tri(cyclo) substituted amide compounds

Country Status (15)

Country Link
US (1) US20080242869A1 (enExample)
EP (1) EP1740560A1 (enExample)
JP (1) JP2007533722A (enExample)
KR (1) KR20060134179A (enExample)
AU (1) AU2005235798A1 (enExample)
BR (1) BRPI0510163A (enExample)
CA (1) CA2563192A1 (enExample)
EA (1) EA012204B1 (enExample)
IL (1) IL178473A0 (enExample)
MA (1) MA28545B1 (enExample)
MX (1) MXPA06012008A (enExample)
NO (1) NO20065260L (enExample)
NZ (1) NZ550567A (enExample)
WO (1) WO2005103021A1 (enExample)
ZA (1) ZA200608489B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
PL375021A1 (en) 2002-10-03 2005-11-14 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
PT1735322E (pt) 2004-04-02 2012-01-12 Novartis Ag Derivados de sulfonamido-tiazolopiridina como activadores de glucoquinase úteis para o tratamento de diabetes de tipo 2
US7781451B2 (en) 2004-04-02 2010-08-24 Novartis Ag Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions
MX2007001650A (es) * 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
JP2009544648A (ja) 2006-07-24 2009-12-17 エフ．ホフマン−ラ ロシュ アーゲー グルコキナーゼ活性化剤としてのピラゾール類
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
US8034819B2 (en) * 2007-03-07 2011-10-11 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
AU2009205070A1 (en) 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CN102089291B (zh) * 2008-04-28 2016-08-17 杏林制药株式会社 环戊基丙烯酰胺衍生物
JP5513492B2 (ja) 2008-05-16 2014-06-04 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
MX2011006006A (es) * 2008-12-08 2011-09-08 Euroscreen Sa Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
UA104742C2 (uk) 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US20130281708A1 (en) 2010-03-18 2013-10-24 Takeda California, Inc. Process for the Production of 2-Amino-5-Fluorothiazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
HK1046139B (zh) * 1999-03-29 2004-12-10 霍夫曼-拉罗奇有限公司 葡糖激酶活化剂
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
BR0110704A (pt) * 2000-05-08 2003-01-28 Hoffmann La Roche Fenil - acetamidas substituìdas e seu uso como ativadores de glicocinase
CA2416229C (en) * 2000-07-20 2007-09-18 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
EP1341774B1 (en) * 2000-12-06 2006-02-01 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
BR0309546A (pt) * 2002-04-26 2005-02-15 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe

Also Published As

Publication number Publication date
MXPA06012008A (es) 2007-01-25
AU2005235798A1 (en) 2005-11-03
BRPI0510163A (pt) 2007-10-02
ZA200608489B (en) 2008-06-25
NO20065260L (no) 2006-11-21
WO2005103021A1 (en) 2005-11-03
EA200601747A1 (ru) 2007-04-27
IL178473A0 (en) 2007-02-11
EP1740560A1 (en) 2007-01-10
KR20060134179A (ko) 2006-12-27
JP2007533722A (ja) 2007-11-22
EA012204B1 (ru) 2009-08-28
US20080242869A1 (en) 2008-10-02
NZ550567A (en) 2010-07-30
MA28545B1 (fr) 2007-04-03

Similar Documents

Publication Publication Date Title
EP1594867B1 (en) Phenylacetamides and their use as glucokinase modulators
CA2576407A1 (en) Substituted phenylacetamides and their use as glucokinase activators
NZ550567A (en) Tri(cyclo) substituted amide compounds
CA2626504A1 (en) Tricyclo substituted amides as glucokinase modulators
JP2006517590A5 (enExample)
WO2007051846A1 (en) Tricyclo substituted amides
KR20030016419A (ko) 알파-아실 및 알파-헤테로원자-치환된 벤젠 아세트아미드글루코키나제 활성화제
CN100567276C (zh) 三（环）取代的酰胺类化合物
HK1082507A1 (en) Phenylacetamides and their use as glucokinase modulators
HK1082507B (en) Phenylacetamides and their use as glucokinase modulators

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued